IFIH1 and dermatomyositis: When autoantibodies to a 140 kDa protein were first discovered in 2005 in patients with clinically amyopathic DM [7] who predominately displayed cutaneous manifestations for abnormally long periods of time (≥6 months) without accompanying muscle weakness [8], subsequent evidence demonstrated that melanoma differentiation-associated gene-5 (MDA5) was the target autoantigen [9].